These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31926204)

  • 1. Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α8-mediated activation of RhoA signaling pathway.
    Cai Q; Chen F; Xu F; Wang K; Zhang K; Li G; Chen J; Deng H; He Q
    Metabolism; 2020 Mar; 104():154140. PubMed ID: 31926204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-125b promotes the NF-κB-mediated inflammatory response in NAFLD via directly targeting TNFAIP3.
    Zhang Q; Yu K; Cao Y; Luo Y; Liu Y; Zhao C
    Life Sci; 2021 Apr; 270():119071. PubMed ID: 33515562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-218-5p promotes hepatic lipogenesis through targeting Elovl5 in non-alcoholic fatty liver disease.
    Wu G; Zhang Y; Liang B; Yin L; Gao M; Zhang H; Xu Y; Han X; Qi Y; Liu F; Xu L
    Biochem Pharmacol; 2024 Aug; 226():116411. PubMed ID: 38972428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in non-alcoholic fatty liver disease via microRNA-200 and the MAPK pathway.
    Wang Y; Zeng Z; Guan L; Ao R
    J Cell Mol Med; 2020 Jun; 24(11):6107-6119. PubMed ID: 32324317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis.
    Shen Y; Cheng L; Xu M; Wang W; Wan Z; Xiong H; Guo W; Cai M; Xu F
    Metabolism; 2023 Sep; 146():155657. PubMed ID: 37422021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
    Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
    World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting miR-27a and miR-142-5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway.
    Teimouri M; Hosseini H; Shabani M; Koushki M; Noorbakhsh F; Meshkani R
    IUBMB Life; 2020 Mar; 72(3):361-372. PubMed ID: 31889412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a.
    Du J; Niu X; Wang Y; Kong L; Wang R; Zhang Y; Zhao S; Nan Y
    Sci Rep; 2015 Nov; 5():16163. PubMed ID: 26537990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2.
    Chen X; Ma H; Gao Y; Jin Y; Ning W; Hou Y; Su J
    Bioengineered; 2021 Dec; 12(1):6738-6747. PubMed ID: 34511037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
    Chen L; Wu N; Kennedy L; Francis H; Ceci L; Zhou T; Samala N; Kyritsi K; Wu C; Sybenga A; Ekser B; Dar W; Atkins C; Meadows V; Glaser S; Alpini G
    Hepatology; 2021 Oct; 74(4):1845-1863. PubMed ID: 33928675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.
    Zhang ZC; Liu Y; Xiao LL; Li SF; Jiang JH; Zhao Y; Qian SW; Tang QQ; Li X
    J Hepatol; 2015 Dec; 63(6):1466-75. PubMed ID: 26272872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
    Xu M; Zheng XM; Jiang F; Qiu WQ
    J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipotoxic hepatocytes promote nonalcoholic fatty liver disease progression by delivering microRNA-9-5p and activating macrophages.
    Liu H; Niu Q; Wang T; Dong H; Bian C
    Int J Biol Sci; 2021; 17(14):3745-3759. PubMed ID: 35261562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
    Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML
    Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.
    Zhang T; Hu J; Wang X; Zhao X; Li Z; Niu J; Steer CJ; Zheng G; Song G
    J Hepatol; 2019 Jan; 70(1):87-96. PubMed ID: 30218679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
    Zheng C; Nie H; Pan M; Fan W; Pi D; Liang Z; Liu D; Wang F; Yang Q; Zhang Y
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116967. PubMed ID: 37506783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.
    Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK
    Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-125b-5p improves pancreatic β-cell function through inhibiting JNK signaling pathway by targeting DACT1 in mice with type 2 diabetes mellitus.
    Yu CY; Yang CY; Rui ZL
    Life Sci; 2019 May; 224():67-75. PubMed ID: 30684546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.